Smith & Nephew stock reports 4.60 percent H1 growth

Published on 09/30/2026 at 17:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Smith & Nephew stock posted USD 3.10 billion in H1 revenue through June 27, 2026. Trading profit reached USD 566.00 million.

Techniker prüfen Implantate im sterilen Reinraum eines Medizintechnik-Werks — Smith & Nephew plc (ISIN GB0009223206) fertigt orthopädische Implantate in sterilen Reinraum-Anlagen mit hoher Präzision, Illustration mit AI erstellt.

Smith & Nephew (ISIN GB0009223206) was trading at EUR 11.95 at Lang & Schwarz on September 30, 2026 at 4:59 p.m. CEST, up 0.84 percent from the EUR 11.85 prior close. The group delivered 4.60 percent reported revenue growth in the first half of 2026, giving the stock a fresh profitability angle despite slower underlying expansion.

Revenue reaches USD 3.10 billion

For the six months ended June 27, 2026, revenue reached USD 3.10 billion, compared with USD 2.96 billion in the year-earlier period. The H1 figure represents reported growth of 4.60 percent and underlying growth of 2.30 percent, according to MetaTrader.

The contrast between reported and underlying growth matters because currency contributed to the headline increase, while the underlying rate shows the operating pace more clearly. Sports Medicine and ENT grew 10.20 percent on a reported basis, whereas Orthopaedics and Advanced Wound Management each recorded negative 0.10 percent underlying growth in the same period.

Profit growth outpaces sales

Trading profit increased 8.10 percent to USD 566.00 million from USD 523.00 million, and the trading profit margin expanded to 18.30 percent from 17.70 percent. Operating profit also rose 4.30 percent to USD 448.00 million, according to MetaTrader.

Cash generation was more mixed. Cash from operations increased 6.90 percent to USD 605.00 million, while free cash flow declined 5.20 percent to USD 231.00 million as spending rose for a UK wound factory and information technology projects. That split leaves margin delivery and the recovery of US knee and hip demand as the key operating measures for the second half.

London listing anchors the quote

Smith & Nephew's ordinary shares are admitted to the London Stock Exchange Main Market under ISIN GB0009223206, as documented by the SEC on September 18, 2026. The listing uses ticker SN.L and is quoted in pence on the primary exchange, while the reference quote for this article remains the euro price at Lang & Schwarz.

At Lang & Schwarz, the stock was trading at EUR 11.95 on September 30, 2026 at 4:59 p.m. CEST, plus 0.84 percent versus the EUR 11.85 prior close of September 29, 2026. The further course of trading is shown by the continuously updated real-time quote of Smith & Nephew stock.